findmyKOL

Imad Tabbara, MD

Basic profile

Hematology / Oncology

ORCIDNone on fileNPI
RegionWashington, DC · NortheastSpecialtyHematology / OncologyFocusOncology
Active KOLEmergingfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Imad Tabbara is an Oncology physician. OpenAlex indexes 76 publications with 3,376 citations (h-index 23).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
76publications

Distinct works indexed by OpenAlex.

3,376citations

Total citations across indexed works.

23h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
57companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

2150 Pennsylvania Ave NW
Washington, DC 200373201

Telephone

202-741-2222

Registry record last updated 8 Jul 2007.

View the NPPES registry record

Industry payments

57 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Musculoskeletal

    67.5%
    RANK Ligand Inhibitor65.3%
    Denosumab100%
    Part B, office-administered12 patients
    Xanthine oxidase inhibitor2.3%
    Allopurinol100%
    Part D<11 patients
  • Cancer & immunology

    9.9%
    Kinase inhibitor4.6%
    Brukinsa63%Imbruvica20%Sprycel17%
    Part D<11 patients
    Thalidomide Analog2.4%
    Revlimid53%Pomalyst47%
    Part D<11 patients

    + 3 more classes in this area

  • Metabolism & gastrointestinal

    5.9%
    Corticosteroid3%
    Prednisone100%
    Part D17 patients
    Serotonin-3 Receptor Antagonist1.6%
    Ondansetron Odt60%Ondansetron Hcl41%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B)35.6% facility · 64.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”